Senti Biosciences, Inc.

Historical 13F Holders

Symbol
SNTI
CUSIP
81726A209
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 81726A209 since 12/18/2024, newest first.

Filer % of Class Filed
New Enterprise Associates 15, L.P. 13D/A Amendment 3
12.1% 3/31/2026
Event 3/27/2026
Celadon Partners SPV 24 13D/A Amendment 3
45.0% 1/20/2026
Event 1/19/2026
Celadon Partners SPV 24 13D/A Amendment 2
45.0% 9/2/2025
Event 8/29/2025
Armistice Capital, LLC 13G/A Amendment 1
4.99% 5/15/2025
Event 3/31/2025
Nantahala Capital Partners Limited Partnership 13G/A Amendment 1 1.9% 5/15/2025
Event 3/31/2025
Nantahala Capital Management, LLC 13G/A Amendment 1
8.1% 5/15/2025
Event 3/31/2025
Nantahala Capital Management, LLC 13G/A Amendment 1
8.1% 5/15/2025
Event 3/31/2025
Celadon Partners SPV 24 13D/A Amendment 1
37.6% 3/17/2025
Event 3/6/2025
Celadon Partners SPV 24 13D
37.6% 3/13/2025
Event 3/6/2025
New Enterprise Associates 15, L.P. 13D/A Amendment 2
14.5% 3/10/2025
Event 3/6/2025
Armistice Capital, LLC 13G
10.0% 2/14/2025
Event 12/31/2024
Nantahala Capital Management, LLC 13G
10.0% 2/14/2025
Event 12/31/2024
Nantahala Capital Partners Limited Partnership 13G 5.9% 2/14/2025
Event 12/2/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 1 3.78 M $4.15 M
2026 Q1 16 5.64 M $4.58 M
2025 Q4 15 5.61 M $5.84 M
2025 Q3 15 5.61 M $7.91 M
2025 Q2 15 6.48 M $13.7 M
2025 Q1 16 5.66 M $19.0 M
2024 Q4 16 667 k $2.34 M
2024 Q3 13 764 k $1.73 M